CGTLive®’s Weekly Rewind – May 24, 2024

News
Article

Review top news and interview highlights from the week ending May 24, 2024.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Atara Submits BLA for Tab-Cel EBV+ PTLD T-Cell Therapy

Tab-Cel is approved under the name Ebvallo in Europe, Switzerland, and United Kingdom.

2. Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies

The Associate Professor of Neurology at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.

3. CRISPR-Editing EBT-101 Therapy Safe, Temporarily Suppresses HIV Infection

Excision is evaluating a higher dose in a second cohort as well as exploring alternative, potentially redosable, delivery methods.

4. Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical Trials

The associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.

5. NKGen’s Autologous NK Therapy Proceeds to Phase 2 Trial for Alzheimer Disease

Most participants had improved or stable cognitive function in a proof-of-concept study.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
Jeffrey Chamberlain, PhD, on Continuing the Marathon of Muscular Dystrophy Research
© 2024 MJH Life Sciences

All rights reserved.